Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Breast Cancer
Interventions: Doxorubicin followed by Paclitaxel, Paclitaxel followed by Doxorubicin; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Asthma, Bronchoconstriction
Interventions: Levalbuterol HFA MDI, Racemic Albuterol; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more

Conditions: Migraine
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more

Conditions: Exercise Physiology, Nutritional Supplementation
Interventions: Caffeine, L-Citrulline, Exogenous Ketone (Beta-Hydroxybutyrate), placebo beverage; Dietary Supplement · Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Overweight, Obesity
Interventions: Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Inherited Retinal Degeneration Associated With RPGR Mutations, Inherited Retinal Degeneration Associated With Biallelic RPE65 Mutations
Interventions: Not listed
Lead sponsor: University College, London; Other
Eligibility: Up to 50 Years
Enrollment: 4,887 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Implantable Defibrillator
Interventions: MRI scan sequences of the head and chest regions, Waiting Period Visit; Device · Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 25
States / cities: Salinas, California • Stanford, California • Hartford, Connecticut + 22 more

Conditions: Achondroplasia
Interventions: BMN 111 administration via Injector Pen, BMN 111 administration via vial and syringe; Combination Product · Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Uveal Melanoma
Interventions: Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteer
Interventions: atirmociclib (PF-07220060); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: Rosuvastatin, Sotorasib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: crizotinib, rifampin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy
Interventions: Lesinurad 400 mg, Metformin 850 mg, Furosemide 40 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Urinary Incontinence
Interventions: PureWick® Urine Collection System, UltraFlex™ Self-Adhering Male External Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 65 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Greenacres City, Florida • Hamilton, New Jersey

Conditions: Healthy Volunteers
Interventions: Treatment A: Mavacamten intact oral capsule, Treatment B: Mavacamten open capsule in suspension, Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Schizophrenia
Interventions: Elpipodect, Moxifloxacin, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Glendale, California • Orange, California • Hallandale, Florida + 1 more

Conditions: Healthy Volunteers
Interventions: Febuxostat XR, Maalox Advance Regular Strength liquid; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
Interventions: Quantitative ultrasound (DeepUSFF); Device
Lead sponsor: Seoul National University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Crohn's Disease
Interventions: GSK1605786 500 mg, Midazolam 3 mg, Pioglitazone 15 mg, Omeprazole 40 mg, Rosuvastatin 10 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Osteoporosis
Interventions: Teriparatide; Drug
Lead sponsor: Pfenex, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Pharmacokinetics
Interventions: DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B; Biological
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo, 250 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 15
States / cities: Phoenix, Arizona • Fresno, California • San Francisco, California + 12 more

Conditions: Anterior Cruciate Ligament (ACL) Reconstruction
Interventions: Gabapentin; Other
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: 12 Years to 18 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Effects of Pre-Run Nutritional Supplements During a Fixed-Pace 5 km Treadmill Run

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and Adolescents

Confirmatory Clinical Trial of the Evera MRI System for Conditionally-safe MRI Access

Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants

Tebentafusp-tebn With LDT in Metastatic UM

Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers

Metformin and Furosemide Drug-Drug Interaction Study

This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

Quantitative Ultrasound (RS85 and R20) for Liver Fat Quantification in MASLD Using MRI-PDFF as Reference

A Study To Evaluate PF-05175157 In Healthy Volunteers

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

A Comparison Study of PF708 and Forteo in Healthy Subjects

A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Gabapentin Premedication for ACL Reconstruction: RCT